Funding Opportunities / RFPs
Currently Available Funding Opportunities / Requests for Proposals (RFPs):
Clinical Trials to Validate AI-Driven Drug Repurposing: now accepting submissions of investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease, where the therapies supported by AI models are already approved. Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial. Budget: up to $100,000, including a 10% institutional match, with additional funds available for community engagement. SUBMISSIONS DUE AUGUST 25, 2025.
- Any unsolved disease is eligible, although there is a preference for rare diseases.
- Both on- and off-patent drugs and biologics are eligible, although there is a preference for off-patent.
- Data from any AI model is eligible, although there is a preference for openly accessible models and for models developed by nonprofits/government.
- The document “Potential AI Model Resources for CWR” is solely available to provide options to prospective clinical researchers and has been developed as just one resource of potential AI models that could be used as part of an RFP submission. The data in “Potential AI Model Resources for CWR” is provided by AI models, not CWR. This is not meant to be an exhaustive list of eligible AI models, and models not included in this list may be eligible for AI validation submissions. This downloadable file will be updated by CWR during the Letter of Intent (LOI) submission window, so be sure to utilize the most recent version. If you have an AI model to include in this list, email Sydney@CuresWithinReach.org for details.
Repurposing Research to Improve Patient Outcomes in Meniere’s Disease and Related Diagnoses: Clinical and Preclinical Projects: for clinical repurposing trials (budgets up to $350,000) and preclinical repurposing research (budgets up to $100,000) in Meniere’s disease as well as other vertigo and hearing loss-related diagnoses, including benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis. LOI DEADLINE CLOSED; SUBMISSIONS UNDER REVIEW
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries 2025: accepting budgets of up to $65,000 for clinical repurposing trials in any disease led by an underresourced researcher in any LMIC, as defined by the World Bank. LOI DEADLINE CLOSED; SUBMISSIONS UNDER REVIEW
Repurposing Research for Chicago 2025: accepting budgets of up to $100,000 for clinical repurposing trials from Chicago area research institutions in one or more of the tracks listed below. LOI DEADLINE CLOSED; SUBMISSIONS UNDER REVIEW
- Track 1 – Health Equity: clinical repurposing trials that 1) address health disparities, including women’s health, among underrepresented patients OR 2) are led by an underrepresented researcher OR both 1) and 2).
- Track 2 – Early Stage Investigators: clinical repurposing trials in any unsolved disease led by a researcher who is within 10 years of completing an advanced degree or medical residency.
- Track 3 – Pediatrics: clinical repurposing trials to address unmet medical needs of pediatric patients, including adding a pediatric arm to an adult clinical repurposing trial.
- Track 4 – Veterans/Military: clinical repurposing trials to address unmet medical needs of US veterans and/or active US military, including but not limited to mental health, PTSD and brain injuries.
If you’re already a ProposalCentral user, log into our new site from the top right corner.
If you don’t have a ProposalCentral login, create a login here.
Closed Funding Opportunities / Requests for Proposals (RFPs):
2024
US Based Repurposing Clinical Trials to Address Health Equity 2024: INVITE ONLY accepting budgets of up to $75,000 for repurposing clinical trials to address health equity, including repurposing clinical trials that EITHER are 1) led by an underrepresented researcher OR 2) address health disparities among underrepresented patients OR 3) both 1) and 2).
Impacting Blood Cancers through Clinical Repurposing Trials 2024: accepting budgets of up to $75,000 from institutions worldwide for clinical repurposing trials targeting any blood cancer, with a preference for trials impacting multiple myeloma and/or myelodysplastic syndromes.
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries 2024: accepting budgets of up to $65,000 for clinical repurposing trials in any disease led by an underresourced researcher in any LMIC, as defined by the World Bank.
Clinical Repurposing Research to Impact Veterans/Military 2024: accepting budgets of up to $75,000 to a U.S.-based institution for a repurposing clinical trial in any disease area impacting veterans or active military, such as mental health, PTSD and brain injuries.
Repurposing Research for Chicago 2024: accepting budgets of up to $100,000 for clinical repurposing trials from Chicago area research institutions in one or more of the following tracks.
- Track 1 – Diversity, Equity and Inclusion: clinical repurposing trials that 1) are led by an underrepresented researcher (as defined by the NIH) OR 2) address health disparities among underrepresented patients (as defined by the NIH) OR both 1) and 2).
- Track 2 – Early Stage Investigators: clinical repurposing trials in any unsolved disease led by a researcher who is within 10 years of completing an advanced degree or medical residency.
- Track 3 – Pediatrics: clinical repurposing trials to address unmet medical needs of pediatric patients, including adding a pediatric arm to an adult clinical repurposing trial.
- Track 4 – Veterans/Military: clinical repurposing trials to address unmet medical needs of US veterans and/or active US military, including but not limited to mental health, post-traumatic stress disorder (PTSD) and brain injuries.
2023
- ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs): for clinical repurposing trials in any disease led by an underserved researcher in any LMIC, as defined by the World Bank – accepting budgets of up to $60,000
- US Based Clinical Repurposing Trials to Address Diversity, Equity and Inclusion (DEI): for clinical repurposing trials in any disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented patients and researchers – accepting budgets of up to $75,000
- Repurposing Research to Address Diversity, Equity and Inclusion in the Greater Chicago Area: for clinical repurposing trials from Chicagoland research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented patients and researchers – accepting budgets of up to $100,000
- Clinical Repurposing Research to Impact Veterans/Military: INVITE ONLY for repurposing clinical trials in any disease area impacting veterans, including mental health, PTSD and brain injuries – up to $75,000
- Repurposing Research to Improve Patient Outcomes in Meniere’s Disease and Related Diagnoses: Clinical and Preclinical Projects: for clinical repurposing trials (budgets up to $100,000) and preclinical repurposing research (budgets up to $50,000) in Meniere’s disease as well as other vertigo and hearing loss-related diagnoses, including benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis
2022
- Drug Repurposing Clinical Trials to Impact Blood Cancers: for clinical repurposing trials testing repurposed drugs in any blood cancer from anywhere in the world – accepting budgets of up to $75,000.
- Repurposing Research to Address Diversity, Equity and Inclusion (DEI) in the Greater Chicago Area: for clinical repurposing trials from Chicagoland research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $100,000.
- US Based Clinical Repurposing Trials to Address Diversity, Equity and Inclusion (DEI): for clinical repurposing trials in any disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $70,000.
- CureAccelerator Live! for Diversity, Equity and Inclusion (DEI) in Rare Diseases: for clinical repurposing trials in any rare disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $70,000.
- ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs): for clinical repurposing trials in any disease led by an underserved researcher in any LMIC, as defined by the World Bank – accepting budgets of up to $50,000.
2021
- Clinical Repurposing Research to Impact Veterans: repurposing clinical trials in any disease area impacting veterans, including mental health, PTSD and brain injuries – up to $50,000
- CureAccelerator Live! for Pediatric Rare Diseases: repurposing clinical trials in any pediatric rare disease – up to $50,000
- Repurposing Research to Improve Clinical Patient Outcomes in Meniere’s Disease and Related Symptoms / Consequences: repurposing clinical trials to address Meniere’s disease and symptoms / consequences of Meniere’s disease, including tinnitus and hearing loss – up to $100,000
- Preclinical Repurposing Research to Address Meniere’s Disease and Related Symptoms / Consequences: repurposing preclinical project to address Meniere’s disease and symptoms / consequences of Meniere’s disease, including tinnitus and hearing loss – up to $50,000
- Repurposing Research Led by a US-Based Racial / Ethnic Minority Principal Investigator: clinical repurposing trials in any disease led by a US-based racial / ethnic minority PI underrepresented in biomedical research, as defined by the NIH – up to $70,000
- Repurposing Research to Address Racial / Ethnic Health Disparities in the Greater Chicago Area: clinical repurposing trials from any research institution in the greater Chicago area to address racial / ethnic health disparities in communities of color as defined by the NIH – up to $80,000
- ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs): clinical repurposing trials led by an underserved researcher in any LMIC, as defined by the World Bank – up to $50,000
2020
- ReGRoW Pilot: clinical repurposing research projects from PIs based in low and lower-middle income countries (LMICs) to find treatments for patients in LMICs
- Rare Blood Cancers and Retinitis Pigmentosa: clinical repurposing research projects – up to $50,000
- Meniere’s Disease: clinical repurposing research projects – up to $100,000
- Meniere’s Disease: pre-clinical repurposing research projects – up to $50,000
- Canine-Focused Comparative Trials: repurposing research projects from PIs based in North America and Europe – up to $25,000
- Chicagoland Clinical Repurposing Trials: repurposing research projects from PIs based in the Chicago area – up to $50,000